UW-Madison presents preclinical findings with radiolabeled ART-101
Nov. 7, 2024
The University of Wisconsin-Madison has synthesized a next-generation prostate-specific member antigen (PSMA)-targeting small molecule, ART-101, for the treatment of advanced prostate cancer.